Cargando…

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection

OBJECTIVES: Ridinilazole (SMT19969) is a narrow-spectrum, non-absorbable antimicrobial with activity against Clostridium difficile undergoing clinical trials. The purpose of this study was to assess the pharmacological activity of ridinilazole and assess the effects on cell morphology. METHODS: Anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bassères, Eugénie, Endres, Bradley T., Khaleduzzaman, Mohammed, Miraftabi, Faranak, Alam, M. Jahangir, Vickers, Richard J., Garey, Kevin W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830417/ https://www.ncbi.nlm.nih.gov/pubmed/26895772 http://dx.doi.org/10.1093/jac/dkv498

Ejemplares similares

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile
por: Corbett, D., et al.
Publicado: (2015)

In Vivo Assessment of SMT19969 in a Hamster Model of Clostridium difficile Infection
por: Weiss, William, et al.
Publicado: (2014)

1369. Combined Analysis of the In Vitro Activity of Ridinilazole (RDZ) Against More Than 500 Clostridium difficile (CD) Clinical Isolates and Impact of RDZ on Cell Morphology
por: Duperchy, Esther, et al.
Publicado: (2018)

Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators
por: Freeman, Jane, et al.
Publicado: (2015)

Community Environmental Contamination of Toxigenic Clostridium difficile
por: Alam, M Jahangir, et al.
Publicado: (2017)

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
por: Sattar, Abdul, et al.
Publicado: (2015)

SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model
por: Baines, S. D., et al.
Publicado: (2015)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

Ridinilazole: a novel antimicrobial for Clostridium difficile infection
por: Cho, Jonathan C., et al.
Publicado: (2019)

A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin
por: Thabit, Abrar K., et al.
Publicado: (2016)

668. Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared with Vancomycin (VAN)
por: Paul, Sumita, et al.
Publicado: (2019)

Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence
por: Goldstein, Ellie J. C., et al.
Publicado: (2014)

A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
por: Vickers, Richard, et al.
Publicado: (2015)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates
por: Goldstein, Ellie J. C., et al.
Publicado: (2013)

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin
por: Thorpe, Cheleste M., et al.
Publicado: (2018)

Ridinilazole: a novel, narrow‐spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile
por: Collins, Deirdre A, et al.
Publicado: (2022)

1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile
por: Mason, Clive, et al.
Publicado: (2021)

1344. Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes From a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

1361. Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for Clostridium difficile Infection (CDI): From Animal Models to Patients
por: Duperchy, Esther, et al.
Publicado: (2018)

2387. Selecting Clostridium difficile Infection (CDI) Outcome Measures Relevant to Public Health Concerns: Experience From a Ridinilazole (RDZ) Phase 2 Trial
por: Vickers, Richard, et al.
Publicado: (2018)

The Enterotoxicity of Clostridium difficile Toxins
por: Sun, Xingmin, et al.
Publicado: (2010)

2398. Effect of Eosinopenia and Binary Toxin on Clostridioides difficile Infection Clinical Outcomes
por: Carlson, Travis J, et al.
Publicado: (2019)

688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
por: Basseres, Eugenie, et al.
Publicado: (2019)

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
por: Bassères, Eugénie, et al.
Publicado: (2020)

Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile
por: Collins, Deirdre A, et al.
Publicado: (2020)

1774. Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

510. First Environmental Investigation of Toxigenic Clostridium difficile Strains in Texas Hospitals
por: Alam, M Jahangir, et al.
Publicado: (2018)

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study
por: Vickers, Richard J, et al.
Publicado: (2017)

First Environmental Investigation of Toxigenic Clostridium difficile at a Large Hospital in Bangladesh
por: Alam, M Jahangir, et al.
Publicado: (2017)

Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids
por: Qian, Xi, et al.
Publicado: (2020)

In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile
por: Begum, Khurshida, et al.
Publicado: (2020)

Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains
por: Endres, Bradley T, et al.
Publicado: (2019)

Toxin B is essential for virulence of Clostridium difficile
por: Lyras, Dena, et al.
Publicado: (2009)

A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021
por: Snydman, D. R., et al.
Publicado: (2023)

Metal Ion Activation of Clostridium sordellii Lethal Toxin and Clostridium difficile Toxin B
por: Genth, Harald, et al.
Publicado: (2016)

Binary Toxin and Death after Clostridium difficile Infection
por: Bacci, Sabrina, et al.
Publicado: (2011)

Spore Formation and Toxin Production in Clostridium difficile Biofilms
por: Semenyuk, Ekaterina G., et al.
Publicado: (2014)

The Role of Rho GTPases in Toxicity of Clostridium difficile Toxins
por: Chen, Shuyi, et al.
Publicado: (2015)

The Regulatory Networks That Control Clostridium difficile Toxin Synthesis
por: Martin-Verstraete, Isabelle, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_npj5r1nnjh8pra928hf5grmkcs